View in EDS

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.

Saved in:
Bibliographic Details
Title: 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.
Authors: Dummer, R.1 (AUTHOR), Flaherty, K.T.2 (AUTHOR), Robert, C.3 (AUTHOR), Arance, A.4 (AUTHOR), de Groot, J.W.B.5 (AUTHOR), Garbe, C.6 (AUTHOR), Gogas, H.J.7 (AUTHOR), Gutzmer, R.8 (AUTHOR), Krajsová, I.9 (AUTHOR), Liszkay, G.10 (AUTHOR), Loquai, C.11 (AUTHOR), Mandala, M.12 (AUTHOR), Schadendorf, D.13 (AUTHOR), Yamazaki, N.14 (AUTHOR), Zohren, F.15 (AUTHOR), Edwards, M.16 (AUTHOR), Ascierto, P.A.17 (AUTHOR)
Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS872-S873. 2p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 152689511
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Dummer%2C+R%2E%22">Dummer, R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Flaherty%2C+K%2ET%2E%22">Flaherty, K.T.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robert%2C+C%2E%22">Robert, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Arance%2C+A%2E%22">Arance, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22de+Groot%2C+J%2EW%2EB%2E%22">de Groot, J.W.B.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Garbe%2C+C%2E%22">Garbe, C.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gogas%2C+H%2EJ%2E%22">Gogas, H.J.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gutzmer%2C+R%2E%22">Gutzmer, R.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krajsová%2C+I%2E%22">Krajsová, I.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liszkay%2C+G%2E%22">Liszkay, G.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Loquai%2C+C%2E%22">Loquai, C.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mandala%2C+M%2E%22">Mandala, M.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schadendorf%2C+D%2E%22">Schadendorf, D.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yamazaki%2C+N%2E%22">Yamazaki, N.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zohren%2C+F%2E%22">Zohren, F.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Edwards%2C+M%2E%22">Edwards, M.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ascierto%2C+P%2EA%2E%22">Ascierto, P.A.</searchLink><relatesTo>17</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2021 Supplement 5, Vol. 32, pS872-S873. 2p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152689511
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2021.08.1426
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: S872
    Titles:
      – TitleFull: 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dummer, R.
      – PersonEntity:
          Name:
            NameFull: Flaherty, K.T.
      – PersonEntity:
          Name:
            NameFull: Robert, C.
      – PersonEntity:
          Name:
            NameFull: Arance, A.
      – PersonEntity:
          Name:
            NameFull: de Groot, J.W.B.
      – PersonEntity:
          Name:
            NameFull: Garbe, C.
      – PersonEntity:
          Name:
            NameFull: Gogas, H.J.
      – PersonEntity:
          Name:
            NameFull: Gutzmer, R.
      – PersonEntity:
          Name:
            NameFull: Krajsová, I.
      – PersonEntity:
          Name:
            NameFull: Liszkay, G.
      – PersonEntity:
          Name:
            NameFull: Loquai, C.
      – PersonEntity:
          Name:
            NameFull: Mandala, M.
      – PersonEntity:
          Name:
            NameFull: Schadendorf, D.
      – PersonEntity:
          Name:
            NameFull: Yamazaki, N.
      – PersonEntity:
          Name:
            NameFull: Zohren, F.
      – PersonEntity:
          Name:
            NameFull: Edwards, M.
      – PersonEntity:
          Name:
            NameFull: Ascierto, P.A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2021 Supplement 5
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 32
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1